Estrogen for Alzheimer's disease in women

Randomized, double-blind, placebo-controlled trial

Victor W. Henderson, A. Paganini-Hill, B. L. Miller, R. J. Elble, P. F. Reyes, D. Shoupe, C. A. McCleary, R. A. Klein, Ann Hake, Martin Farlow

Research output: Contribution to journalArticle

486 Citations (Scopus)

Abstract

Background: AD, the most prevalent cause of dementia, affects twice as many women as men. Therapeutic options are limited, but results of prior studies support the hypothesis that estrogen treatment may improve symptoms of women with this disorder. Methods: Forty-two women with mild-to-moderate dementia due to AD were enrolled into a randomized, double-blind, placebo- controlled, parallel-group trial of unopposed conjugated equine estrogens (1.25 mg/day) for 16 weeks. Results: Outcome data were available for 40 women at 4 weeks and 36 women at 16 weeks. At both 4 and 16 weeks, there were no significant differences or statistical trends between treatment groups on the primary outcome measure (the cognitive subscale of the Alzheimer's Disease Assessment Scale), clinician-rated global impression of change, or caregiver- rated functional status. Exploratory analyses of mood and specific aspects of cognitive performance also failed to demonstrate substantial group differences. Conclusions: Although conclusions are limited by small sample size and the possibility of a type II error, results suggest that short-term estrogen therapy does not improve symptoms of most women with AD. These findings do not address possible long-term effects of estrogen in AD, possible interactions between estrogen and other treatment modalities, or putative effects of estrogen in preventing or delaying onset of this disorder.

Original languageEnglish
Pages (from-to)295-301
Number of pages7
JournalNeurology
Volume54
Issue number2
StatePublished - Jan 25 2000

Fingerprint

Alzheimer Disease
Estrogens
Placebos
Dementia
Therapeutics
Conjugated (USP) Estrogens
Sample Size
Caregivers
Outcome Assessment (Health Care)

Keywords

  • AD
  • Clinical trial
  • Cognition
  • Estrogen
  • Mood Women

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Henderson, V. W., Paganini-Hill, A., Miller, B. L., Elble, R. J., Reyes, P. F., Shoupe, D., ... Farlow, M. (2000). Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology, 54(2), 295-301.

Estrogen for Alzheimer's disease in women : Randomized, double-blind, placebo-controlled trial. / Henderson, Victor W.; Paganini-Hill, A.; Miller, B. L.; Elble, R. J.; Reyes, P. F.; Shoupe, D.; McCleary, C. A.; Klein, R. A.; Hake, Ann; Farlow, Martin.

In: Neurology, Vol. 54, No. 2, 25.01.2000, p. 295-301.

Research output: Contribution to journalArticle

Henderson, VW, Paganini-Hill, A, Miller, BL, Elble, RJ, Reyes, PF, Shoupe, D, McCleary, CA, Klein, RA, Hake, A & Farlow, M 2000, 'Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial', Neurology, vol. 54, no. 2, pp. 295-301.
Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D et al. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology. 2000 Jan 25;54(2):295-301.
Henderson, Victor W. ; Paganini-Hill, A. ; Miller, B. L. ; Elble, R. J. ; Reyes, P. F. ; Shoupe, D. ; McCleary, C. A. ; Klein, R. A. ; Hake, Ann ; Farlow, Martin. / Estrogen for Alzheimer's disease in women : Randomized, double-blind, placebo-controlled trial. In: Neurology. 2000 ; Vol. 54, No. 2. pp. 295-301.
@article{e86c7697878e49a080ed0cd9ade10a8d,
title = "Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial",
abstract = "Background: AD, the most prevalent cause of dementia, affects twice as many women as men. Therapeutic options are limited, but results of prior studies support the hypothesis that estrogen treatment may improve symptoms of women with this disorder. Methods: Forty-two women with mild-to-moderate dementia due to AD were enrolled into a randomized, double-blind, placebo- controlled, parallel-group trial of unopposed conjugated equine estrogens (1.25 mg/day) for 16 weeks. Results: Outcome data were available for 40 women at 4 weeks and 36 women at 16 weeks. At both 4 and 16 weeks, there were no significant differences or statistical trends between treatment groups on the primary outcome measure (the cognitive subscale of the Alzheimer's Disease Assessment Scale), clinician-rated global impression of change, or caregiver- rated functional status. Exploratory analyses of mood and specific aspects of cognitive performance also failed to demonstrate substantial group differences. Conclusions: Although conclusions are limited by small sample size and the possibility of a type II error, results suggest that short-term estrogen therapy does not improve symptoms of most women with AD. These findings do not address possible long-term effects of estrogen in AD, possible interactions between estrogen and other treatment modalities, or putative effects of estrogen in preventing or delaying onset of this disorder.",
keywords = "AD, Clinical trial, Cognition, Estrogen, Mood Women",
author = "Henderson, {Victor W.} and A. Paganini-Hill and Miller, {B. L.} and Elble, {R. J.} and Reyes, {P. F.} and D. Shoupe and McCleary, {C. A.} and Klein, {R. A.} and Ann Hake and Martin Farlow",
year = "2000",
month = "1",
day = "25",
language = "English",
volume = "54",
pages = "295--301",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Estrogen for Alzheimer's disease in women

T2 - Randomized, double-blind, placebo-controlled trial

AU - Henderson, Victor W.

AU - Paganini-Hill, A.

AU - Miller, B. L.

AU - Elble, R. J.

AU - Reyes, P. F.

AU - Shoupe, D.

AU - McCleary, C. A.

AU - Klein, R. A.

AU - Hake, Ann

AU - Farlow, Martin

PY - 2000/1/25

Y1 - 2000/1/25

N2 - Background: AD, the most prevalent cause of dementia, affects twice as many women as men. Therapeutic options are limited, but results of prior studies support the hypothesis that estrogen treatment may improve symptoms of women with this disorder. Methods: Forty-two women with mild-to-moderate dementia due to AD were enrolled into a randomized, double-blind, placebo- controlled, parallel-group trial of unopposed conjugated equine estrogens (1.25 mg/day) for 16 weeks. Results: Outcome data were available for 40 women at 4 weeks and 36 women at 16 weeks. At both 4 and 16 weeks, there were no significant differences or statistical trends between treatment groups on the primary outcome measure (the cognitive subscale of the Alzheimer's Disease Assessment Scale), clinician-rated global impression of change, or caregiver- rated functional status. Exploratory analyses of mood and specific aspects of cognitive performance also failed to demonstrate substantial group differences. Conclusions: Although conclusions are limited by small sample size and the possibility of a type II error, results suggest that short-term estrogen therapy does not improve symptoms of most women with AD. These findings do not address possible long-term effects of estrogen in AD, possible interactions between estrogen and other treatment modalities, or putative effects of estrogen in preventing or delaying onset of this disorder.

AB - Background: AD, the most prevalent cause of dementia, affects twice as many women as men. Therapeutic options are limited, but results of prior studies support the hypothesis that estrogen treatment may improve symptoms of women with this disorder. Methods: Forty-two women with mild-to-moderate dementia due to AD were enrolled into a randomized, double-blind, placebo- controlled, parallel-group trial of unopposed conjugated equine estrogens (1.25 mg/day) for 16 weeks. Results: Outcome data were available for 40 women at 4 weeks and 36 women at 16 weeks. At both 4 and 16 weeks, there were no significant differences or statistical trends between treatment groups on the primary outcome measure (the cognitive subscale of the Alzheimer's Disease Assessment Scale), clinician-rated global impression of change, or caregiver- rated functional status. Exploratory analyses of mood and specific aspects of cognitive performance also failed to demonstrate substantial group differences. Conclusions: Although conclusions are limited by small sample size and the possibility of a type II error, results suggest that short-term estrogen therapy does not improve symptoms of most women with AD. These findings do not address possible long-term effects of estrogen in AD, possible interactions between estrogen and other treatment modalities, or putative effects of estrogen in preventing or delaying onset of this disorder.

KW - AD

KW - Clinical trial

KW - Cognition

KW - Estrogen

KW - Mood Women

UR - http://www.scopus.com/inward/record.url?scp=0034711656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034711656&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 295

EP - 301

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -